BAMCO Inc
VKTX icon

BAMCO Inc’s Viking Therapeutics VKTX Stock Holding History

BAMCO Inc’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-125,486
Closed -$4.08M – 371
2026
Q1 		$4.08M Sell
125,486
-341
-0.3% -$11K 0.01% 253
2025
Q4 		$4.43M Sell
125,827
-910
-0.7% -$32.2K 0.01% 257
2025
Q3 		$3.33M Hold
126,737
– – 0.01% 266
2025
Q2 		$3.36M Sell
126,737
-275,470
-68% -$7.25M 0.01% 262
2025
Q1 		$9.71M Buy
402,207
+16,735
+4% +$529K 0.03% 237
2024
Q4 		$15.5M Sell
385,472
-89,172
-19% -$5.08M 0.04% 216
2024
Q3 		$30M Sell
474,644
-28,175
-6% -$1.65M 0.08% 178
2024
Q2 		$26.7M Buy
502,819
+9,560
+2% +$627K 0.08% 185
2024
Q1 		$40.4M Buy
493,259
+183,192
+59% +$8.15M 0.11% 155
2023
Q4 		$5.77M Buy
+310,067
New +$4.06M 0.02% 257

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

BAMCO Inc's VKTX Position: Q2 2026 in Review

BAMCO Inc sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 125,486 shares — an estimated $4.08M sold.

BAMCO Inc first reported a position in VKTX in Q4 2023 and held it in 10 quarters. The position peaked at $40.4M in Q1 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • BAMCO Inc reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • BAMCO Inc sold 125,486 Viking Therapeutics shares in Q2 2026, an estimated $4.08M.
  • BAMCO Inc first reported a position in Viking Therapeutics in Q4 2023 and held it in 10 quarters.
  • BAMCO Inc's Viking Therapeutics position peaked at $40.4M in Q1 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on BAMCO Inc's 13F filing for Q2 2026, filed 14 Aug 2026.